Injectable Hydrogel Reverses Liver Fat in Animal Study
Researchers at National Taiwan University tested a self-healing biomaterial that reduced hepatic fat in rats.
What the Preclinical Study Evaluated
Bioengineers at National Taiwan University (NTU) have developed an injectable hydrogel that reduced hepatic fat and inflammation in rodent models of metabolic dysfunction-associated steatotic liver disease (MASLD). The preclinical investigation appeared in the journal Advanced Healthcare Materials on November 4, 2026. The research team evaluated whether local delivery of a self-repairing biomaterial could improve tissue architecture in damaged livers.
Metabolic dysfunction-associated steatotic liver disease currently affects approximately 38% of the global adult population. The condition develops alongside metabolic syndrome, yet authorized pharmaceutical treatments remain limited in scope and clinical efficacy. Professor Yung-Te Hou and Professor Shan-hui Hsu led the project alongside Professor Kenji Osafune of Kyoto University.
How the Composite Biomaterial Operates
The experimental hydrogel acts as a temporary functional matrix that degrades inside the liver to release therapeutic compounds. The structure relies on a dynamic polymer network formed by reversible Schiff-base crosslinking between chitosan-phenol (Chi-Ph) and difunctionalized polyethylene glycol (DP-PEG). These chemical bonds separate and re-form under mechanical stress, allowing the gel to recover its physical shape after needle delivery.
To mimic natural hepatic tissue, the authors incorporated decellularized liver matrix (DLM) and hepatocyte spheroids into the polymer base. The DLM component is isolated through portal vein perfusion decellularization, which strips away cellular debris while preserving the structural proteins of the native extracellular matrix (ECM). The formulation also integrates 0.1 weight percent tannic acid (TA), a plant polyphenol that stiffens the scaffold to match natural liver tissue and inhibits lipid accumulation.
What the Laboratory and Animal Experiments Found
Rats treated with the composite material showed marked improvements in liver pathology within two weeks of injection. The researchers tested the formulation, designated 0.1% TA-CDS, in Sprague-Dawley (SD) rats that developed steatotic liver disease from an eight-week high-fat diet (HFD). Following hepatic injection, the hydrogel degraded and released tannic acid directly into local circulation.
The intervention lowered liver fat accumulation, attenuated inflammatory signaling, and restored cellular architecture across the treated tissue. Serum biochemical markers and lipid metabolic profiles also improved compared to untreated controls. The authors corroborated these cellular effects in laboratory cultures using human induced pluripotent stem cell (iPSC)-derived hepatocyte-like cell spheroids (HLS).
Why Human Trials Remain Necessary
The reported improvements occurred exclusively in laboratory cell models and high-fat diet rodent models. Animal physiology processes synthetic materials differently than human metabolic systems, and long-term degradation kinetics require independent study. Direct hepatic injection also carries procedural risks that differ fundamentally from oral medications.
The researchers have not announced dates for clinical trials or submitted the material for human safety reviews. Translating complex biomaterials containing decellularized tissues and cellular spheroids introduces substantial manufacturing and preservation hurdles. Patients must view these findings as exploratory bioengineering data rather than an available clinical intervention.
What Patients Can Do for Metabolic Liver Health
Individuals diagnosed with hepatic steatosis must rely on established clinical guidelines rather than early-stage material science developments. Current metabolic management focuses on sustained dietary changes, regular physical activity, and medical management of comorbid insulin resistance or dyslipidemia.
Patients managing elevated liver enzymes or hepatic fat accumulation should talk to their clinician about validated assessment tools and evidence-based lifestyle interventions.
Related Articles
Obesity Drugs and Brain Protection: What the Evidence Shows
A review in Science analyzes whether obesity drugs like semaglutide protect brain function,...
Read article MetabolismWegovy Pill Approved by Australian Regulators for Weight Management
Australia's Therapeutic Goods Administration approved Wegovy tablets for weight management,...
Read article MetabolismStanford Study Identifies BRP as AI-Found Appetite Suppressant
Stanford researchers used artificial intelligence to identify BRP, a natural peptide that...
Read article MetabolismEarlier Bedtime Linked to Greater Weight Loss in Prediabetes Trial
An 8-week randomized trial from NYU Rory Meyers College of Nursing linked earlier bedtimes to...
Read articleWant a clinician to work up your metabolic numbers?
Opt Health runs fasting insulin, A1C, a full lipid panel and 50+ other markers, then builds a treatment plan — GLP-1s included where they're appropriate — with a physician who reviews the data with you directly.
See Opt Health's metabolic program →Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Understand Your Health Better
Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results